{
  "id": "5e44af0848dab47f26000015",
  "type": "summary",
  "question": "What is the mechanism of action of ozanimod?",
  "ideal_answer": "Ozanimod is a specific and potent small molecule modulator of the sphingosine 1-phosphate receptor 1 (S1PR1) and receptor 5 (S1PR5), which has shown therapeutic benefit in clinical trials of relapsing multiple sclerosis and ulcerative colitis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28398597",
    "http://www.ncbi.nlm.nih.gov/pubmed/26990079",
    "http://www.ncbi.nlm.nih.gov/pubmed/29608575",
    "http://www.ncbi.nlm.nih.gov/pubmed/31492652",
    "http://www.ncbi.nlm.nih.gov/pubmed/27144850",
    "http://www.ncbi.nlm.nih.gov/pubmed/28765121",
    "http://www.ncbi.nlm.nih.gov/pubmed/31492651",
    "http://www.ncbi.nlm.nih.gov/pubmed/30930775",
    "http://www.ncbi.nlm.nih.gov/pubmed/29500302",
    "http://www.ncbi.nlm.nih.gov/pubmed/28783871",
    "http://www.ncbi.nlm.nih.gov/pubmed/29125718",
    "http://www.ncbi.nlm.nih.gov/pubmed/26239599",
    "http://www.ncbi.nlm.nih.gov/pubmed/30043658",
    "http://www.ncbi.nlm.nih.gov/pubmed/27049060"
  ],
  "snippets": [
    {
      "text": "Ozanimod is a novel, selective, oral sphingosine-1-phosphate (1 and 5) receptor modulator in development for multiple sclerosis and inflammatory bowel disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emerging strategies to interfere with cellular adhesion processes involved in lymphocyte recruitment are discussed, including both integrin blockade (natalizumab, vedolizumab, etrolizumab) and sphingosine-1-phosphate receptor inhibition (fingolimod, ozanimod).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28765121",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ozanimod (RPC1063) is an oral selective modulator of the sphingosine-1-phosphate 1 and 5 receptors under development for the treatment of relapsing multiple sclerosis and inflammatory bowel disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In addition, there are three more specific S1P agonists in late stages of development: siponimod, ponesimod, and ozanimod. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29500302",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29608575",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Ozanimod (RPC1063) is a specific and potent small molecule modulator of the sphingosine 1-phosphate receptor 1 (S1PR1) and receptor 5 (S1PR5), which has shown therapeutic benefit in clinical trials of relapsing multiple sclerosis and ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29608575",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The sphingosine-1-phosphate receptor-1 (S1P __sub__ 1 __end_sub__ ) agonist ozanimod ameliorates ulcerative colitis, yet its mechanism of action is unknown.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27049060",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This review will focus on SM drugs approved and under development, including JAK inhibitors (tofacitinib, filgotinib, upadacitinib, peficitinib) and S1PR agonists (KRP-203, fingolimod, ozanimod, etrasimod, amiselimod), and their mechanism of action.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30930775",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\n\nOzanimod is a sphingosine 1-phosphate receptor modulator, which selectively binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31492652",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\n\nOzanimod, a sphingosine 1-phosphate receptor modulator, selectively binds to receptor subtypes 1 and 5 with high affinity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31492651",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ozanimod is a novel, selective, oral sphingosine-1-phosphate (1 and 5) receptor modulator in development for multiple sclerosis and inflammatory bowel disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The sphingosine-1-phosphate receptor-1 (S1P 1 ) agonist ozanimod ameliorates ulcerative colitis, yet its mechanism of action is unknown.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27049060",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\n\nOzanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that induces peripheral lymphocyte sequestration, potentially decreasing the number of activated lymphocytes circulating to the gastrointestinal tract.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27144850",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Ozanimod, an oral immunomodulator, selectively targets sphingosine 1-phosphate receptors 1 and 5.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30043658",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28398597",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The sphingosine-1-phosphate receptor-1 ( S1P ) agonist ozanimod ameliorates ulcerative colitis , yet its mechanism of action is unknown",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27049060",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "More selective S1P receptor agents-ponesimod ( ACT128800) , siponimod ( BAF312) , ozanimod ( RPC1063) , ceralifimod ( ONO-4641) , GSK2018682 , and MT-1303-are still in relatively early stages of development , but phase I and II trials showed promising efficacy and safety",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26239599",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Ozanimod (RPC1063) is an oral selective modulator of the sphingosine-1-phosphate 1 and 5 receptors under development for the treatment of relapsing multiple sclerosis and inflammatory bowel disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ozanimod is a novel, selective, oral sphingosine-1-phosphate (1 and 5) receptor modulator in development for multiple sclerosis and inflammatory bowel disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nOzanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that induces peripheral lymphocyte sequestration, potentially decreasing the number of activated lymphocytes circulating to the gastrointestinal tract.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27144850",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The sphingosine-1-phosphate receptor-1 (S1P1) agonist ozanimod ameliorates ulcerative colitis, yet its mechanism of action is unknown.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27049060",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26990079",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": []
}